Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.01 (-4.39%)
Close on Nov 20, 2026Market cap $47.94MP/E –Yield –
Heron Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Heron Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$12.14M. For fiscal 2025 it was -$27.91M. The highest annual figure on record is -$5.56M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.91M | – |
| FY2024 | Dec 31, 2024 | -$24.24M | – |
| FY2023 | Dec 31, 2023 | -$60.33M | – |
| FY2022 | Dec 31, 2022 | -$148.74M | – |
| FY2021 | Dec 31, 2021 | -$206.38M | – |
| FY2020 | Dec 31, 2020 | -$191.63M | – |
| FY2019 | Dec 31, 2019 | -$131.73M | – |
| FY2018 | Dec 31, 2018 | -$200.98M | – |
| FY2017 | Dec 31, 2017 | -$172.85M | – |
| FY2016 | Dec 31, 2016 | -$137.23M | – |
| FY2015 | Dec 31, 2015 | -$79.61M | – |
| FY2014 | Dec 31, 2014 | -$61.72M | – |
| FY2013 | Dec 31, 2013 | -$42.45M | – |
| FY2012 | Dec 31, 2012 | -$17.98M | – |
| FY2011 | Dec 31, 2011 | -$8.23M | – |
| FY2010 | Dec 31, 2010 | -$5.56M | – |
| FY2009 | Dec 31, 2009 | -$11.00M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.18M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.33M | -54.7% |
| Q2 FY2025 | Jun 30, 2025 | -$11.08M | -602.3% |
| Q1 FY2025 | Mar 31, 2025 | -$8.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.42M | – |
| Q3 FY2024 | Sep 30, 2024 | $2.94M | – |
| Q4 FY2023 | Dec 31, 2023 | $2.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.97M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.44M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$44.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$45.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$63.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$55.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$42.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$58.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.88M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$25.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$51.16M | – |
| Q4 FY2018 | Dec 31, 2018 | -$36.96M | – |
| Q3 FY2018 | Sep 30, 2018 | -$39.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$62.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$62.62M | – |
| Q4 FY2017 | Dec 31, 2017 | -$48.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$40.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$32.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$51.52M | – |
| Q4 FY2016 | Dec 31, 2016 | -$39.21M | – |
| Q3 FY2016 | Sep 30, 2016 | -$36.65M | – |
See a number that looks wrong?